MX2015009141A - Formulaciones de albu-bche, preparacion y usos de las mismas. - Google Patents
Formulaciones de albu-bche, preparacion y usos de las mismas.Info
- Publication number
- MX2015009141A MX2015009141A MX2015009141A MX2015009141A MX2015009141A MX 2015009141 A MX2015009141 A MX 2015009141A MX 2015009141 A MX2015009141 A MX 2015009141A MX 2015009141 A MX2015009141 A MX 2015009141A MX 2015009141 A MX2015009141 A MX 2015009141A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- present
- lyophilized pharmaceutical
- provides
- aqueous
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona una composición acuosa farmacéutica que comprende a la proteína de fusión cuya secuencia de aminoácidos se establece como SEQ ID NO: 1 y una solución acuosa que comprende fosfato de sodio de 40 a 60 mM. La presente invención además proporciona una composición farmacéutica liofilizada, una solución reconstituida, un empaque sellado que comprende a la composición farmacéutica liofilizada, y un vial que comprende a la solución reconstituida o a la solución liofilizada. La presente invención también proporciona un método para producir la composición farmacéutica liofilizada y el empaque sellado. La presente invención también proporciona un método para tratar a un humano que tiene comportamiento de búsqueda de cocaína, y métodos para usar la composición acuosa farmacéutica y la composición farmacéutica liofilizada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752740P | 2013-01-15 | 2013-01-15 | |
| PCT/US2014/011401 WO2014113359A1 (en) | 2013-01-15 | 2014-01-14 | Formulations of albu-bche, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015009141A true MX2015009141A (es) | 2016-03-16 |
Family
ID=51165300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009141A MX2015009141A (es) | 2013-01-15 | 2014-01-14 | Formulaciones de albu-bche, preparacion y usos de las mismas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9409662B2 (es) |
| EP (1) | EP2945703A4 (es) |
| AR (1) | AR094481A1 (es) |
| CA (1) | CA2896793A1 (es) |
| HK (1) | HK1217670A1 (es) |
| MX (1) | MX2015009141A (es) |
| WO (1) | WO2014113359A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896793A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
| CA2986323A1 (en) * | 2015-07-13 | 2017-01-19 | Philip Morris Products S.A. | Producing an aerosol-forming composition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2048263T3 (es) | 1988-11-01 | 1994-03-16 | Sanol Arznei Schwarz Gmbh | Composicion liofilizada de mdm y metodo para su fabricacion. |
| US6001625A (en) | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| WO2002044361A2 (en) | 2000-11-28 | 2002-06-06 | Applied Molecular Evolution, Inc. | Eukaryotic expression libraries based on double lox recombination and methods of use |
| US20030096401A1 (en) | 2000-11-28 | 2003-05-22 | Huse William D. | Eukaryotic expression libraries and methods of use |
| JP2004528014A (ja) | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１融合タンパク質 |
| US20030153062A1 (en) | 2001-12-20 | 2003-08-14 | Watkins Jeffry D. | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US7070973B2 (en) | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| IL142875A (en) | 2001-04-30 | 2009-08-03 | Avigdor Shafferman | PEG-linked cholinesterases for the detoxification of circulating organophosphorus |
| US6989261B2 (en) | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US7049121B2 (en) | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| WO2003054182A2 (en) | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
| CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050136044A1 (en) | 2003-12-04 | 2005-06-23 | Watkins Jeffry D. | Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
| US20060039870A1 (en) | 2004-08-20 | 2006-02-23 | Turner Jeffrey D | Pulmonary delivery of enzymatic medical countermeasures |
| WO2006026717A2 (en) | 2004-08-30 | 2006-03-09 | Tercica, Inc. | Method and device for diagnosing and treating insulin-like growth factor deficiency disorders |
| US20070259348A1 (en) | 2005-05-03 | 2007-11-08 | Handylab, Inc. | Lyophilized pellets |
| US7438904B1 (en) | 2005-10-04 | 2008-10-21 | University Of Kentucky Research Foundation | High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same |
| WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BRPI0714380A2 (pt) * | 2006-07-10 | 2013-03-05 | Univ Columbia | composiÇÕes anticocaÍna e tratamento |
| KR20110132327A (ko) * | 2009-01-16 | 2011-12-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CN102711795A (zh) * | 2009-12-08 | 2012-10-03 | 泰华制药工业有限公司 | 用于治疗可卡因滥用的BChE白蛋白融合体 |
| SG194458A1 (en) | 2011-04-12 | 2013-12-30 | Endocyte Inc | Solid pharmaceutical composition |
| CA2892626A1 (en) | 2012-12-12 | 2014-06-19 | Teva Pharmaceutical Industries Ltd. | Fusion of human growth hormone and albumin, formulation and uses thereof |
| WO2014113358A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Lyophilization process |
| CA2896793A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
-
2014
- 2014-01-14 CA CA2896793A patent/CA2896793A1/en not_active Abandoned
- 2014-01-14 US US14/155,021 patent/US9409662B2/en not_active Expired - Fee Related
- 2014-01-14 AR ARP140100135A patent/AR094481A1/es unknown
- 2014-01-14 MX MX2015009141A patent/MX2015009141A/es unknown
- 2014-01-14 WO PCT/US2014/011401 patent/WO2014113359A1/en active Application Filing
- 2014-01-14 EP EP14740413.1A patent/EP2945703A4/en not_active Withdrawn
-
2016
- 2016-05-17 HK HK16105646.9A patent/HK1217670A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014113359A1 (en) | 2014-07-24 |
| AR094481A1 (es) | 2015-08-05 |
| EP2945703A4 (en) | 2016-08-31 |
| US9409662B2 (en) | 2016-08-09 |
| US20140199283A1 (en) | 2014-07-17 |
| CA2896793A1 (en) | 2014-07-24 |
| HK1217670A1 (zh) | 2017-01-20 |
| EP2945703A1 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201809694PA (en) | Antibody neutralizing human respiratory syncytial virus | |
| MX2012000036A (es) | Vacuna. | |
| MX2021010519A (es) | Proteinas f de rsv de prefusion y su uso. | |
| NZ711567A (en) | Antibody formulations | |
| MX345700B (es) | Proteinas f del vrs modificadas y metodos de uso de las mismas. | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| MX350013B (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
| WO2015089492A3 (en) | Dna antibody constructs and method of using same | |
| EA201490610A1 (ru) | Соединения и способы усиления врожденных иммунных ответов | |
| EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
| EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| IN2014DN06920A (es) | ||
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| MX2015009141A (es) | Formulaciones de albu-bche, preparacion y usos de las mismas. | |
| NZ712713A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| IN2014DN09445A (es) | ||
| MX349837B (es) | Composicion de transglutaminasa seca. | |
| NZ613554A (en) | Caprylate viral deactivation | |
| WO2015108856A3 (en) | Methods for enhancing the delivery of active agents |